Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sylvia Janetzki

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Journal of Immunological Methods|January 17, 2002
A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assaysJeffrey R Currier, Ellen G Kuta, Ellen Turk, et al.
Science Translational Medicine|November 11, 2011
Harmonization of immune biomarker assays for clinical studiesSjoerd H van der Burg, Michael Kalos, Cécile Gouttefangeas, et al.
Journal of Translational Medicine|July 13, 2011
A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocolsSebastian Attig, Leah Price, Sylvia Janetzki, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|June 22, 2013
A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI)Lisa K McNeil, Leah Price, Cedrik M Britten, et al.
Cancer Immunology, Immunotherapy : CII|March 5, 2009
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine ConsortiumCedrik Michael Britten, Sylvia Janetzki, Leah Ben-Porat, et al.
Immunity|October 17, 2009
"MIATA"-minimal information about T cell assaysSylvia Janetzki, Cedrik M Britten, Michael Kalos, et al.
Cancer Immunology, Immunotherapy : CII|November 10, 2012
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocolsHelene Filbert, Sebastian Attig, Nicole Bidmon, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2007
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Sylvia Janetzki, Katherine S Panageas, Leah Ben-Porat, et al.
The AAPS Journal|April 26, 2023
Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene TherapyBoris Gorovits, Mitra Azadeh, George Buchlis, et al.
Journal for Immunotherapy of Cancer|November 29, 2016
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerationsKevin K Dobbin, Alessandra Cesano, John Alvarez, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Journal of Immunological Methods|January 17, 2002
A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assaysJeffrey R Currier, Ellen G Kuta, Ellen Turk, et al.
Science Translational Medicine|November 11, 2011
Harmonization of immune biomarker assays for clinical studiesSjoerd H van der Burg, Michael Kalos, Cécile Gouttefangeas, et al.
Journal of Translational Medicine|July 13, 2011
A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocolsSebastian Attig, Leah Price, Sylvia Janetzki, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|June 22, 2013
A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI)Lisa K McNeil, Leah Price, Cedrik M Britten, et al.
Cancer Immunology, Immunotherapy : CII|March 5, 2009
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine ConsortiumCedrik Michael Britten, Sylvia Janetzki, Leah Ben-Porat, et al.
Immunity|October 17, 2009
"MIATA"-minimal information about T cell assaysSylvia Janetzki, Cedrik M Britten, Michael Kalos, et al.
Cancer Immunology, Immunotherapy : CII|November 10, 2012
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocolsHelene Filbert, Sebastian Attig, Nicole Bidmon, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2007
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Sylvia Janetzki, Katherine S Panageas, Leah Ben-Porat, et al.
The AAPS Journal|April 26, 2023
Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene TherapyBoris Gorovits, Mitra Azadeh, George Buchlis, et al.
Journal for Immunotherapy of Cancer|November 29, 2016
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerationsKevin K Dobbin, Alessandra Cesano, John Alvarez, et al.
Pageof 4